Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN PLASTIC CONTAINER versus TRAVASOL 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN PLASTIC CONTAINER versus TRAVASOL 10 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% M IN PLASTIC CONTAINER vs TRAVASOL 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% M is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral/enteral nutrition. The 'M' formulation includes electrolytes and trace elements. Amino acids are incorporated into endogenous proteins, serving as substrates for gluconeogenesis, oxidative metabolism, and neurotransmitter synthesis.
Travasol 10% (amino acids injection) provides essential and non-essential amino acids for protein synthesis and nitrogen equilibrium in patients unable to obtain adequate nutrition orally or enterally. Amino acids are building blocks for proteins; they also serve as substrates for gluconeogenesis and other metabolic pathways.
Intravenous administration; typical adult dose is 1 to 2 g amino acids/kg/day, corresponding to 30 to 60 mL/kg/day of 3.5% solution; infusion rate not to exceed 0.1 g amino acids/kg/hour.
Intravenous infusion: 500 mL to 2 L per day, administered at a rate not exceeding 4 mL/kg/h. Typical adult dose is 1-2 g protein/kg/day (equivalent to 10-20 mL/kg/day of 10% solution). Rate and volume are adjusted based on patient's metabolic needs and clinical status.
None Documented
None Documented
Variable; amino acids have short plasma half-lives (minutes to hours) due to rapid cellular uptake and metabolism; no meaningful terminal half-life for the mixture.
Not applicable as a single entity; constituent amino acids have half-lives varying from minutes to hours (e.g., 10-30 min for most). Clinical context: continuous infusion maintains steady state.
100% renal; amino acids are deaminated and metabolized to urea, which is excreted renally; minimal (<1%) biliary/fecal excretion.
Renal excretion of infused amino acids and their metabolites; excess nitrogen excreted as urea in urine. ~90-95% of infused amino acids are utilized or excreted renally. Fecal excretion negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution